These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11420824)

  • 1. [Initial success with topical immunomodulators. A creme for skin cancer? (interview by Renate Jackle)].
    Hengge U
    MMW Fortschr Med; 2001 May; 143(21):11. PubMed ID: 11420824
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiple basal cell carcinomas after radiation treatment: successful treatment with topical imiquimod.
    Santiago Sánchez-Mateos D; Goiriz Valdés R; Daudén Tello E
    Clin Exp Dermatol; 2010 Mar; 35(2):199-200. PubMed ID: 19486047
    [No Abstract]   [Full Text] [Related]  

  • 3. Nonsurgical therapy holds promise for basal cell carcinoma.
    Oncology (Williston Park); 1999 Jul; 13(7):1044. PubMed ID: 10442350
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease.
    Fisher GH; Lang PG
    Arch Dermatol; 2003 Jul; 139(7):945-7. PubMed ID: 12873904
    [No Abstract]   [Full Text] [Related]  

  • 5. [Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil].
    Florin V; Vercambre-Darras S; Piette F; Mortier L
    Ann Dermatol Venereol; 2008; 135(8-9):603-4. PubMed ID: 18789300
    [No Abstract]   [Full Text] [Related]  

  • 6. New cream to treat skin cancer? [news].
    Mayo Clin Health Lett; 2001 Mar; 19(3):4. PubMed ID: 11242841
    [No Abstract]   [Full Text] [Related]  

  • 7. 'Rub on' treatment for basal-cell carcinoma.
    Kerr C
    Lancet Oncol; 2002 Apr; 3(4):201. PubMed ID: 12067676
    [No Abstract]   [Full Text] [Related]  

  • 8. [Topical immunomodulator against skin cancer. Does the cream replace the knife? (interview by Dr. Judith Neumaier)].
    Hauschild A
    MMW Fortschr Med; 2005 Sep; 147(37):21. PubMed ID: 16193872
    [No Abstract]   [Full Text] [Related]  

  • 9. Imiquimod: a topically applied link between innate and acquired immunity.
    Hurwitz DJ; Pincus L; Kupper TS
    Arch Dermatol; 2003 Oct; 139(10):1347-50. PubMed ID: 14568839
    [No Abstract]   [Full Text] [Related]  

  • 10. Adjuvant treatment with topical 5% imiquimod cream for resected stage IIIb melanoma.
    Tiodorovic-Zivkovic D; Argenziano G; Catricalà C; Ferrara G; Giorgio CM; Moscarella E; Zalaudek I
    Eur J Dermatol; 2011; 21(3):410-1. PubMed ID: 21515443
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: "Imiquimod 5% cream for the treatment of periocular basal cell carcinoma".
    Pakdel F; Kashkouli MB
    Ophthalmic Plast Reconstr Surg; 2011; 27(4):305; author reply 305-6. PubMed ID: 20966793
    [No Abstract]   [Full Text] [Related]  

  • 12. Topical and light-based treatments for basal cell carcinoma.
    Robinson JK; Hernandez C; Anderson ER; Nickoloff B
    Semin Cutan Med Surg; 2003 Sep; 22(3):171-6. PubMed ID: 14649584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe.
    Gollnick H; Barona CG; Frank RG; Ruzicka T; Megahed M; Tebbs V; Owens M; Stampone P
    Eur J Dermatol; 2005; 15(5):374-81. PubMed ID: 16172048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical application of imiquimod for the treatment of high-risk facial basal cell carcinoma in Gorlin syndrome.
    Vereecken P; Monsieur E; Petein M; Heenen M
    J Dermatolog Treat; 2004 Apr; 15(2):120-1. PubMed ID: 15204165
    [No Abstract]   [Full Text] [Related]  

  • 15. Superficial and nodular basal cell carcinomas treated with an immune response modifier: a report of seven patients.
    Bianchi L; Costanzo A; Campione E; Nisticò S; Chimenti S
    Clin Exp Dermatol; 2003 Nov; 28 Suppl 1():24-6. PubMed ID: 14616808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasodilatory adverse events associated with topical imiquimod 5 percent cream.
    Jacobs AA; Snavely N; Markus J; Rosen T
    Dermatol Online J; 2008 Apr; 14(4):4. PubMed ID: 18627726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cream to be tested as skin cancer care.
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):621. PubMed ID: 12503207
    [No Abstract]   [Full Text] [Related]  

  • 18. Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream.
    Chapman MS; Spencer SK; Brennick JB
    Arch Dermatol; 2003 Jul; 139(7):943-4. PubMed ID: 12873902
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of multiple basal cell carcinomas in the scalp with imiquimod 5% cream.
    Hannuksela-Svahn A; Nordal E; Christensen OB
    Acta Derm Venereol; 2000; 80(5):381-2. PubMed ID: 11200841
    [No Abstract]   [Full Text] [Related]  

  • 20. Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up.
    Vidal D; Matías-Guiu X; Alomar A
    Arch Dermatol; 2007 Feb; 143(2):266-8. PubMed ID: 17310012
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.